Print Page   |   Contact Us   |   Sign In   |   Join AHS
Community Search
Sign In


4/6/2019 » 6/8/2019
Next Generation Migraine Therapies

Next Generation Migraine Therapies
Register Map this EventMap this Event Tell a Friend About This EventTell a Friend
Next Generation Migraine Therapies

The Next Generation Migraine Therapies (NGMT) will highlight recent updated epidemiological data on the scope and distribution of Chronic and Episodic Migraine, practical methods for diagnosing Chronic and Episodic Migraine, recent insights into mechanisms, and setting the stage for improving treatment outcomes.

 Export to Your Calendar 4/6/2019 to 6/8/2019
When: 04/06/2019
7:45 am
Where: Map this event »
See Registration Form for Locations
United States
Contact: AHS Headquarters

Online registration is available until: 6/2/2019
« Go to Upcoming Event List  

This program is designed for neurologist, family practitioners, internal medicine, psychologists and other health care professionals who would like more information on the proper diagnosis and treatment of chronic migraine patients.


The Next Generation Migraine Therapies (NGMT) programs will be presented on Saturdays in the following cities this Spring:

Saturday, April 6, 2019
Sheraton San Diego Hotel & Marina-Bay Tower
1590 Harbor Island Drive
San Diego, CA 92101

Saturday, May 18, 2019
Westin Dallas Galleria
13340 Dallas Parkway
Dallas, TX

Saturday, June 8, 2019
Marriott Marquis New York
1535 Broadway

New York, NY

Who Should Attend
This program is designed for Neurologists, Family Practitioners, Internists, and other health professionals who would like more information on the proper diagnosis and treatment of chronic migraine patients.

Educational Objectives

  • Recognize the lack of awareness of the basic science and therapeutic potential of CGRP mAbs in the prevention of migraine.
  • Identify mAbs, particularly CGRP and its receptor, provide effective prophylaxis of migraine.
  • Address the need for greater understanding of how to apply new information about migraine pathophysiology to specific patients and potential treatments.
  • Review data on the effectiveness and safety of mAbs in the treatment of migraine and learn how results in key sub-populations can help them predict which patients are likely to respond to treatment with CGRP mAbs.
CME Statement 

AHS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. AHS takes responsibility for the content, quality, and scientific integrity of this CME activity. AHS designates AMA PRA Category 1 credit(s)™ for this medical education activity, Comprehensive Migraine Education Program, for a maximum of 4.0 AMA PRA Category 1 Credit(s)™ for the morning program, 3.50 AMA PRA Category 1 Credit(s)™ for Workshop 1 and 3.5 AMA PRA Category 1 Credit(s)™ for Workshop 2.


This Live activity, Next Generation Migraine Therapies, from 04/06/2019 - 06/08/2019, has been reviewed and is acceptable for up to  8.25 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Headache Society® 19 Mantua Rd. Mount Royal, NJ 08061 Phone: 856-423-0043 Fax: 856-423-0082